Influence of chronic hormone replacement therapy on left ventricular mass and serum-ACE activity

Blood Pressure

Volumn 19, Issue 5, 2010, Pages 295-300

  Manhem, Karin ^a   Ghanoum, Bachar ^a   Johansson, Magnus ^a   Milsom, Ian ^b   Gustafsson, Helena ^b  

^a Institute of Medicine   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

HRT; Hypertension; LVM; Postmenopausal; RAAS; Women

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESTRADIOL; ESTROGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ENZYME ACTIVITY; FEMALE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE MASS; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT RESPONSE;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; POSTMENOPAUSE; TREATMENT OUTCOME;

EID: 77957045964     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2010.488050     Document Type: Article

References (32)

1. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Comparative risk assessment group. Selected major risk factors Lancet. 2002;360:1347-1360.
2. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension. 2001;37:1199-1208.
3. Staessen JA, Celis H, Fagard R. The epidemiology of the association between hypertension and menopause. J Hum Hypertens. 1998;12:587-592.
4. Kannel WB. Left ventricular hypertrophy as a risk factor in arterial hypertension. Eur Heart J. 1992;13 Suppl D:82-88.
5. Kahan T. The importance of left ventricular hypertropgy in human hypertension. J Hypertens. 1998;16 Supp l7:S23 - 29.
6. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345-352.
7. Verdecciha P, Schillaci G, Borgioni C, Ciuci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998; 97:48-54. (Pubitemid 28036154)
8. Marcus R, Krause L, Weder AB, Dominguez-Meja A, Schork NJ, Julius S. Sex-specific determinants of increased left ventricular mass in the Tecumseh Blood Pressure Study. Circulation. 1994;90:928-936
9. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1995; 273:199-208.
10. Manhem K, Ahlm H, Milsom I, Svensson A. Transdermal oestrogen reduces daytime blood pressure in hypertensive women.J Hum Hypertens. 1998;12:323-327.
11. Schillaci G, Verdecchia P, Borgioni C, Ciucci A, Porcellati C. Early cardiac changes after menopause. Hypertension. 1998; 32:764-769.
12. Duygu H, Akman L, Ozerkan F, Akercan F, Zoghi M, Nalbantgil S, et al. Comparison of the effects of new and conventional hormone replacement therapies on left ventricular diastolic function in healthy postmenopausal women: A Doppler and ultrasonic backscatter study. Int J Cardiovasc Imaging. 2009;25:387-396.
13. Grohé C, Kahlert S, Löb bert S, Stimpel M, Karas RH, Vetter H, et al. Cardiac myocytes and fibroblasts contain functional estrogen receptors. FEBS Lett. 1997;416:107-112.
14. Babiker FA, Lips D, Meyer R, Delvaux E, Zandberg P, Janssen B, et al. Estrogen receptor beta protects the murine heart against left ventricular hyperthrophy. Aterioscler Thromb Vasc Biol. 2006;26:1524-1530.
15. Schmeider RE, Martus P, Klinbeil A. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of randomized double-blind studies. JAMA. 1996;275: 1507-1513.
16. Hayward CS, Webb C, Collins P. Effect of sex hormones on cardiac mass. Lancet. 2001;357:1354-1356.
17. Proudler AJ, Ahmed AI, Crook D, Fogelman I, Rymer JM, Stevenson JC. Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. Lancet. 1995;346:89-90.
18. Seely EW, Brosnihan KB, Jeunemaitres X, Okamura K, Williams GH, Hollenberg NK, et al. Effects of conjugated oestrogen and droloxifen on the renin - angiotensin system, blood pressure and renal blood flow in postmenopausal women. Clin Endocrinology. 2004;60:315-321.
19. Sahn DJ. Recommendations regarding quantification in M-mode echocardiography. Results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083.
20. Devereux RB. Echocardiographic assessment of left ventricular hypertrophy. C omparison to necropsy findings. Am J Cardiol. 1986;57:450-458.
21. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Bartoccini C, et al. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. JACC. 1995;25: 871-878.
22. Kronik G. Comparative value of eight M-mode ventricular echocardiographic formulas for determining left ventricular stroke volume. Circulation. 1979;60:1308-1316.
23. Sanada M, Higashi Y, Nakagawa K, Sasaki S, Kodama I, Sakashita T, et al. Estrogen replacement therapy in postmenopausal women augments reactive hyperemia in the forearm by reducing angiotensin converting enzyme activity. Atherosclerosis.. 2001 Oct;158:391-397. (Pubitemid 32913649)
24. Modena MG, Muia Jr N, Aveta P, Molinari R, Rossi R. Effects of transdermal 17 β-estradiol on left ventricular anatomy and performance in hypertensive women. Hypertens. 1999;34:1041-1046.
25. Modena MG, Molinari R, Muia Jr N, Castelli A, Pala F, Rossi R. Double-blind randomized placebo-controlled study of transdermal estrogen replacement therapy on hypertensive postmenopausal women. Am J Hypertens. 1999;12:1000-1008.
26. Prime DD, Brosnihan KB, Herrington DM. Effects of hormone therapy on blood pressure and the renin - angiotensin system in postmenopausal women. Minerva Cardioangiol. 2007;55:477-485.
27. Miya Y, Sumino H, Ichikawa S, Nakamura T, Kanda T, Kumakura H, et al. Effects of hormone replacement therapy on left ventricular hypertrophy and growth-promoting factors in hypertensive postmenopausal women. Hyptens Res. 2002;25:153-159.
28. Takeda-Matsubara Y, Nakagami H, Iwai M, Cui TX, Shiuchi T, Akishita M, et al. Estrogen activates phosphatases and antagonizes growth-promoting effect of angiotensin II. Hypertension. 2002 Jan;39:41-45
29. Umeda M, Ichikawa S, Kanda T, Sumino H, Kobayashi I. Hormone replacement therapy increases plasma level of angiotensin II in postmenopausal hypertensive women. Am J Hypertens. 2001;14:206-211.
30. Ichikawa A, Sumino H, Ogawa T, Ichikawa S, Nitta K. Effects of long-term transdermal hormone replacement therapy on the renin - angiotensin - aldosterone system, plasma bradykinin levels and blood pressure in normotensive postmenopausal women. Geriatr Gerontol Int2008;8:259-264.
31. Dubey RK, Imthurn B, Barton M, Jackson EK. Vascular consequences of menopause and hormone therapy: Importance of timing of treatment and type of estrogen. Cardiovasc Res.. 2005;66:295-306.
32. Dahlöf B. Structural cardiovascular changes in essential hypertension: Studies on the effect of antihypertensive therapy. Thesis, Sweden; 1992. ISBN: 91-628-0592-4.